InMed Pharmaceuticals Inc. (INM)
INM Stock Price Chart
Explore InMed Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze INM price movements and trends.
INM Company Profile
Discover essential business fundamentals and corporate details for InMed Pharmaceuticals Inc. (INM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 May 2014
Employees
13.00
Website
https://www.inmedpharma.comCEO
Eric A. Adams Chem., M.I.B.
Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
INM Financial Timeline
Browse a chronological timeline of InMed Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 10 Feb 2026
Upcoming earnings on 12 Nov 2025
Upcoming earnings on 26 Sept 2025
Earnings released on 12 May 2025
EPS came in at -$1.94 , while revenue for the quarter reached $1.80M .
Earnings released on 12 Feb 2025
EPS came in at -$3.64 , while revenue for the quarter reached $772.53M .
Earnings released on 14 Nov 2024
EPS came in at -$54.20 , while revenue for the quarter reached $936.16K .
Stock split effective on 14 Nov 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 27 Sept 2024
EPS came in at -$3.80 , while revenue for the quarter reached $938.46K , missing expectations by -47.57%.
Earnings released on 14 May 2024
EPS came in at -$3.60 , while revenue for the quarter reached $863.50K , missing expectations by -51.76%.
Earnings released on 13 Feb 2024
EPS came in at -$3.80 , while revenue for the quarter reached $933.78K , missing expectations by -17.36%.
Earnings released on 14 Nov 2023
EPS came in at -$15.20 , while revenue for the quarter reached $1.25M , missing expectations by -10.07%.
Earnings released on 29 Sept 2023
EPS came in at -$12.92 surpassing the estimated -$85.00 by +84.80%, while revenue for the quarter reached $1.74M , beating expectations by +443.49%.
Earnings released on 15 May 2023
EPS came in at -$12.00 surpassing the estimated -$90.00 by +86.67%, while revenue for the quarter reached $764.09K , beating expectations by +138.03%.
Earnings released on 17 Feb 2023
EPS came in at -$18.20 surpassing the estimated -$90.00 by +79.78%, while revenue for the quarter reached $350.12K , missing expectations by -29.98%.
Earnings released on 11 Nov 2022
EPS came in at -$81.20 surpassing the estimated -$85.00 by +4.47%, while revenue for the quarter reached $234.25K , missing expectations by -53.15%.
Earnings released on 23 Sept 2022
EPS came in at -$258.40 falling short of the estimated -$110.00 by -134.91%, while revenue for the quarter reached $399.63K , missing expectations by -46.72%.
Stock split effective on 7 Sept 2022
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2022
EPS came in at -$125.00 falling short of the estimated -$115.00 by -8.70%, while revenue for the quarter reached $247.63K , missing expectations by -20.01%.
Earnings released on 14 Feb 2022
EPS came in at -$155.00 falling short of the estimated -$120.00 by -29.17%, while revenue for the quarter reached $207.89K , beating expectations by +66.31%.
Earnings released on 10 Nov 2021
EPS came in at -$125.00 surpassing the estimated -$175.00 by +28.57%.
Earnings released on 24 Sept 2021
EPS came in at -$205.00 falling short of the estimated -$170.00 by -20.59%.
Earnings released on 13 May 2021
EPS came in at -$205.00 falling short of the estimated -$120.00 by -70.83%.
Earnings released on 11 Feb 2021
EPS came in at -$185.00 falling short of the estimated -$120.00 by -54.17%.
Earnings released on 17 Dec 2020
EPS came in at -$5.75 .
INM Stock Performance
Access detailed INM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.